Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Journal of Hospital Marketing
|
March 6, 1987
Strategic marketing for health care institutions: an encyclopedic approach
L R Hegg, D Meyer
European Journal of Gynaecological Oncology
|
January 1, 1993
Breast cancer control programme in developing countries
J A Pinotti, A C Barros, R Hegg, et al.
Breast Cancer Research and Treatment
|
May 1, 1990
Tissue carcinoembryonic antigen in the prognosis of early invasive breast cancer
R Hegg, A Z De Souza, C B Pestana, et al.
Gynecologic Oncology
|
December 9, 2008
Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for neoadjuvant chemotherapy
S Mendes, S R Graziani, T S Vitório, et al.
Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas
|
May 10, 2012
Effect of neoadjuvant chemotherapy on low-density lipoprotein (LDL) receptor and LDL receptor-related protein 1 (LRP-1) receptor in locally advanced breast cancer
L A Pires, R Hegg, F R Freitas, et al.
American Journal of Clinical Oncology
|
October 1, 1995
Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience
S Bruno, V L Puerto, E Mickiewicz, et al.
Journal of Inorganic Biochemistry
|
September 18, 2017
Protein oxidation involved in Cys-Tyr post-translational modification
Susan E Hromada, Adam M Hilbrands, Elysa M Wolf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 25, 2013
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
A Schneeweiss, S Chia, T Hickish, et al.
Current Medical Research and Opinion
|
March 28, 2001
A phase II trial of fractionated vinorelbine/doxorubicin as first-line therapy for advanced breast cancer
R Hegg, M A Costa, M Perdicaris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2016
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
R Bell, J Brown, M Parmar, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Journal of Hospital Marketing
|
March 6, 1987
Strategic marketing for health care institutions: an encyclopedic approach
L R Hegg, D Meyer
European Journal of Gynaecological Oncology
|
January 1, 1993
Breast cancer control programme in developing countries
J A Pinotti, A C Barros, R Hegg, et al.
Breast Cancer Research and Treatment
|
May 1, 1990
Tissue carcinoembryonic antigen in the prognosis of early invasive breast cancer
R Hegg, A Z De Souza, C B Pestana, et al.
Gynecologic Oncology
|
December 9, 2008
Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for neoadjuvant chemotherapy
S Mendes, S R Graziani, T S Vitório, et al.
Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas
|
May 10, 2012
Effect of neoadjuvant chemotherapy on low-density lipoprotein (LDL) receptor and LDL receptor-related protein 1 (LRP-1) receptor in locally advanced breast cancer
L A Pires, R Hegg, F R Freitas, et al.
American Journal of Clinical Oncology
|
October 1, 1995
Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience
S Bruno, V L Puerto, E Mickiewicz, et al.
Journal of Inorganic Biochemistry
|
September 18, 2017
Protein oxidation involved in Cys-Tyr post-translational modification
Susan E Hromada, Adam M Hilbrands, Elysa M Wolf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 25, 2013
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
A Schneeweiss, S Chia, T Hickish, et al.
Current Medical Research and Opinion
|
March 28, 2001
A phase II trial of fractionated vinorelbine/doxorubicin as first-line therapy for advanced breast cancer
R Hegg, M A Costa, M Perdicaris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2016
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
R Bell, J Brown, M Parmar, et al.
Page
of 2